Therapeutic and preventive effects of an epidermal growth factor receptor inhibitor on oral squamous cell carcinoma

Journal of International Medical Research

Volumn 40, Issue 2, 2012, Pages 455-466

  Sun, Z ^a   Ge, H ^a   Liu, H ^b   Fu, Z ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Chemoprevention; Epidermal growth factor receptor (EGFR); Oral cancer; PD153035; Tyrosine kinase inhibitor

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; DIMETHYLBENZ[A]ANTHRACENE; EPIDERMAL GROWTH FACTOR RECEPTOR; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHEEK POUCH; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; FEMALE; HAMSTER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; NUDE MOUSE; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

EID: 84860450254     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001204000207     Document Type: Article

References (27)

1. Nagpal JK, Das BR: Oral cancer: reviewing the present understanding of its molecular mechanism and exploring the future directions for its effective management. Oral Oncology 2003; 39: 213-221.
2. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. Funk GF, Karnell LH, Robinson RA, et al: Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head Neck 2002; 24: 165-180.
4. Janne PA, Taffaro ML, Salgia R, et al: Inhibition of epidermal growth factor receptor signaling in malignant pleural methothelioma. Cancer Res 2002; 62: 5242-5247.
5. Nicholson RI, Gee JM, Harper ME: EGFR and cancer prognosis. Eur J Cancer 2001; 37(suppl 4): S9-S15.
6. Ono M, Kuwano M: Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 2006; 12: 7242-7251.
7. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
8. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
9. Burtness B, Goldwasser MA, Flood W, et al: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23: 8646-8654.
10. Sun Z, Sood S, Li N, et al: Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch by topical application of a dual inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 tyrosine kinases. Oral Oncol 2008; 44: 652-657.
11. Fry DW, Kraker AJ, McMichael A, et al: A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994; 265: 1093-1095.
12. Boschelli DH: 4-Anilino-3-quinoline carbonitriles: an emerging class of kinase inhibitors. Curr Top Med Chem 2002; 2: 1051-1063.
13. Bos M, Mendelsohn J, Kim YM, et al: PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res 1997; 3: 2099-2106.
14. Marshall J: Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 2006; 107: 1207-1218.
15. Barnes L, Eveson JW, Reichart P, et al (eds): Pathology & Genetics. Head and Neck Tumours (World Health Organization Classification of Tumours). Lyon: International Agency for Research on Cancer (IARC) Press, 2005.
16. Prenzel N, Fischer OM, Streit S, et al: The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001; 8: 11-31.
17. Grandis JR, Tweardy DJ: Elevated levels of transforming growth factor α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579-3584.
18. Ishitoya J, Toriyama M, Oguchi N, et al: Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck. Br J Cancer 1989; 59: 559-562.
19. Ang KK, Berkey BA, Tu X, et al: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-7356.
20. Taoudi Benchekroun M, Saintigny P, Thomas SM, et al: Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) 2010; 3: 800-809.
21. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82: 241-250.
22. Morgillo F, Lee HY: Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist Updat 2005; 8: 298-310.
23. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792.
24. Sequist LV, Waltman BA, Dias-Santagata D, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.
25. Cohen EE, Rosen F, Stadler WM, et al: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-1987.
26. Soulieres D, Senzer NN, Vokes EE, et al: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77-85.
27. Jiang B, Liu F, Yang L, et al: Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer. J Int Med Res 2011; 39: 1392-1401.